Generic Geodon Availability

Geodon is a brand name of ziprasidone, approved by the FDA in the following formulation(s):

GEODON (ziprasidone hydrochloride - capsule;oral)

  • Manufacturer: PFIZER
    Approval date: February 5, 2001
    Strength(s): EQ 20MG BASE [RLD] [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]

GEODON (ziprasidone hydrochloride - suspension;oral)

  • Manufacturer: PFIZER INC
    Approval date: March 29, 2006
    Strength(s): EQ 10MG BASE/ML [RLD]

GEODON (ziprasidone mesylate - injectable;intramuscular)

  • Manufacturer: PFIZER
    Approval date: June 21, 2002
    Strength(s): EQ 20MG BASE/ML [RLD]

Has a generic version of Geodon been approved?

A generic version of Geodon has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Geodon and have been approved by the FDA:

ziprasidone hydrochloride capsule;oral

  • Manufacturer: APOTEX CORP
    Approval date: March 2, 2012
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]
  • Manufacturer: DR REDDYS LABS INC
    Approval date: March 2, 2012
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]
  • Manufacturer: LUPIN PHARMS
    Approval date: March 2, 2012
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]
  • Manufacturer: MYLAN PHARMS INC
    Approval date: October 10, 2013
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]
  • Manufacturer: SANDOZ INC
    Approval date: June 1, 2012
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]
  • Manufacturer: WOCKHARDT LTD
    Approval date: September 5, 2012
    Strength(s): EQ 20MG BASE [AB], EQ 40MG BASE [AB], EQ 60MG BASE [AB], EQ 80MG BASE [AB]

Note: No generic formulation of the following products are available.

  • ziprasidone hydrochloride - suspension;oral
  • ziprasidone mesylate - injectable;intramuscular

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Geodon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
    Patent 6,110,918
    Issued: August 29, 2000
    Inventor(s): Busch; Frank R. & Rose; Carol A.
    Assignee(s): Pfizer Inc
    Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 Antagonist The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
    Patent expiration dates:
    • March 26, 2017
  • Ziprasidone formulations
    Patent 6,150,366
    Issued: November 21, 2000
    Inventor(s): Arenson; Daniel R. & Busch; Frank Robert & Hausberger; Angela G. & Rasadi; Bijan
    Assignee(s): Pfizer Inc.
    Compositions comprising crystalline ziprasidone free base or crystalline ziprasidone hydrochloride particles having a mean particle size less than 85 .mu.m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to treat psychoses such as schizophrenia.
    Patent expiration dates:
    • May 27, 2019
      ✓ 
      Drug product
    • May 27, 2019
      ✓ 
      Patent use: TREATENT OF PSYCHOSIS
      ✓ 
      Drug product
  • Inclusion complexes of aryl-heterocyclic salts
    Patent 6,232,304
    Issued: May 15, 2001
    Inventor(s): Kim; Yesook & Johnson; Kevin C. & Shanker; Ravi M.
    Assignee(s): Pfizer Inc.
    Compositions of matter comprising a pharmaceutically acceptable salt of an aryl-heterocyclic compound, such as ziprasidone, in a cyclodextrin. Preferred cyclodextrins are SBECD and HPBCD. The composition can comprise a dry mixture, a dry inclusion complex or an aqueous solution. The salt/cyclodextrin inclusion complex preferably provides an amount of ziprasidone of at least 2.5 mgA/ml when the complex is dissolved in water at 40% w/v. A variety of ziprasidone salts are preferred, including the mesylate, esylate, besylate, tartrate, napsylate, and tosylate.
    Patent expiration dates:
    • April 1, 2017
  • Method of treating psychiatric conditions
    Patent 6,245,766
    Issued: June 12, 2001
    Inventor(s): Watsky; Eric J.
    Assignee(s): Pfizer Inc
    A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
    Patent expiration dates:
    • December 18, 2018
      ✓ 
      Patent use: TREATMENT OF BIPOLAR DISORDER
  • Inclusion complexes of aryl-heterocyclic salts
    Patent 6,399,777
    Issued: June 4, 2002
    Inventor(s): Yesook; Kim & Kevin C.; Johnson & Ravi M.; Shanker
    Assignee(s): Pfizer Inc.
    The esylate, mesylate, and tartrate salts of ziprasidone exhibit excellent solubilities in cyclodextrins.
    Patent expiration dates:
    • April 1, 2017
  • Ziprasidone suspension
    Patent 7,175,855
    Issued: February 13, 2007
    Inventor(s): Arenson; Daniel R. & Qi; Hong
    Assignee(s): Pfizer Inc.
    Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if setting occurs.
    Patent expiration dates:
    • May 18, 2020
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
Hide
(web1)